Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
GRIDAI TECHNOLOGIES CORP (GRDX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.67-14.00%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for GRDX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Secure additional capital through equity or debt | A primary condition in GRIDAI TECHNOLOGIES CORP's published investment case. The stated target is Raise >=$2.54 million in financing in 2026-Q1 or later. | Improving | Fails to raise at least $2.54 million in financing over next 4 quarters | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 18, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, speculative business with a weak recent financial record and volatile management execution. The current long-term thesis is on watch, and confidence in the evidence is low.
GRDX carries a valuation premium to peers, while its losses and weak results point to a difficult operating picture. The evidence says the premium reflects optionality, or the chance that future developments create value, but does not show that the full mix of expensive valuation, weak results, and turbulence is priced in.
Near term, losses may remain a pressure point: operating losses widened from the first to the second quarter of 2026, while the company continues to seek financing. A late filing led to a Nasdaq compliance notice, and recent earnings have been erratic, adding execution risk around the next report.
Over the multi-year view, the thesis hinges on whether management can address listing compliance, secure financing, and control operating losses. Near-term sector signals matter too: continued strength from Healthcare bellwethers could support the sector backdrop, while weaker results or guidance, alongside a weakening jobs report, could add pressure.
Over the next 1 to 3 years, GRDX remains a low-confidence, high-risk thesis that depends on better execution and financing progress; the recent M&A agreements offer a potential source of change, but the evidence is thin on their effects. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company is working to regain Nasdaq compliance, which is critical to avoid delisting. |
| Intact |
| Fails to regain Nasdaq compliance by end of 2026 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce operating losses from current levels | Operating losses of $3.61 million in 2026-Q1 show the need for cost control. | Broken | Operating losses worsen beyond -$3.61 million in next 4 quarters | Operating income: $-13.107M FY2026-Q2; GAAP. Published target: Reduce operating losses below -$3.61 million in next 4 quarters. Target period is not explicitly aligned with this observation. Aug 21, 2026-13,106,760 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-4.95 → $-4.95 · observed estimates
$0.03B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-07-25 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-07-26 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-07-27 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-07-28 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-07-29 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-07-30 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-07-31 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-01 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-02 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-03 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-04 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-05 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-06 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-07 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-08 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-09 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-10 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-12 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-13 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-14 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-15 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-16 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-17 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-18 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-19 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-20 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-21 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-22 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-23 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-24 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-25 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-26 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-27 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-28 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-29 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-30 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-08-31 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-01 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-02 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-03 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-04 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-05 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-06 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-07 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-08 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-09 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-10 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-11 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-12 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-13 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-14 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-15 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-16 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-17 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-18 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-19 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-20 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-21 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-22 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-23 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-24 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-25 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-26 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-27 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-28 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-29 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-09-30 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-01 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-02 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-03 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-04 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-05 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-06 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-07 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-08 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-09 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-10 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-11 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-12 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-13 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-14 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-15 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-16 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-17 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-18 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-19 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-20 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-21 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-22 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-23 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-24 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-25 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-26 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-27 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-28 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-29 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-30 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-10-31 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-11-01 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-11-02 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-11-03 | $-4.95 | $27,507,000 | 1 / 1 |
| 2026-11-04 | $-4.95 | $27,507,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.